Newsletter

476060 - Onconic Therapeutics, Inc.

476060 Summary
Biopharma
Stock Price & Overview
₩16,440 -670 (-3.92%) Close · Sep 4, 2026 KST
KOSDAQ | ₩KRW | Close: ₩16,440  ≈ US$12  ·  Market cap ₩0.7tn (≈ $533m)
Why this page exists. Korean issuers file to DART, not the SEC, and almost nothing is published in English. Titles here are translated; where kstock has read the filing, the row carries the explanation and the amount in won and dollars. How we pick »

476060 DART Filings

DART

Appointment, dismissal or early departure of an independent director

Filing09/03/26title translated
DART

Material matter affecting investment judgment (clinical trial plan amendment approved)

Filing09/02/26title translated
DART

Half-Year Report

Periodic08/12/26title translated
DART

Material matter affecting investment judgment (clinical trial result)

Filing07/14/26title translated
DART

Material matter affecting investment judgment (clinical trial plan amendment approved)

Filing07/02/26title translated
DART

Material matter affecting investment judgment (clinical trial plan amendment applied for)

Filing06/10/26title translated
DART

Material matter affecting investment judgment (clinical trial plan amendment approved)

Filing06/02/26title translated
DART

Material matter affecting investment judgment (clinical trial plan amendment applied for)

Filing06/01/26title translated
DART

Quarterly Report

Periodic05/11/26title translated
DART

Material matter affecting investment judgment (clinical trial plan amendment applied for)

Filing05/11/26title translated
3 routine filings (insider holdings reports, IR schedules)DART

Insider / Major Shareholder Holdings Report

Ownership07/03/26title translated
DART

Insider / Major Shareholder Holdings Report

Ownership06/12/26title translated
DART

Insider / Major Shareholder Holdings Report

Ownership05/06/26title translated
13 filings on file, grouped where one event produced many. Source: DART, operated by Korea's Financial Supervisory Service.

Similar to 476060

SymbolLast Price
185750Chong Kun Dang Pharmaceutical Corp.₩68,000
-0.3%
115180Qurient Co., Ltd.₩23,050
+17.3%
476830Rznomics, Inc.₩28,200
+6.8%
003850Boryung Corporation₩9,040
+1.6%
950260Ingenia Therapeutics Inc.(reg.s)₩15,580
-1.5%
085660Chabiotech Co., Ltd.₩8,090
+2.1%
041960Komipharm International Co., Ltd.₩9,710
+3.5%
317450Myungin Pharm₩44,650
+0.0%
001060JW Pharmaceutical₩27,500
+1.3%
456160G2GBIO, Inc.₩37,950
+5.7%
Compare all 48 in Biopharma

What a US investor should know

  • Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
  • Daily limitKorean stocks can move at most ±30% in a session before trading halts.
  • Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
  • ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.